Αρχική World News High-Deductible Health Plans Linked to Delayed Diagnosis and Treatment of Breast Cancer

High-Deductible Health Plans Linked to Delayed Diagnosis and Treatment of Breast Cancer

High-deductible health plans are a popular option for employers looking to maximize their spending on health insurance and keep their employees well-covered. On the surface, these plans often look great, which explains why thousands of companies have switched to them in the last several years. From 2007 to 2017, the number of high-deductible health plans in the U.S. rose from 4.2 percent to 18.9 percent among adults 18 to 64 who had job-based coverage. The number of high-deductible plans without a health savings account (HSA) attached increased from 10.6 percent to 24.5 percent in that same age group.High-deductible health policies often cover certain routine or preventative procedures, then require the individual to pay out-of-pocket for any other procedures up to their deductible limit, after which the insurance covers most or all of the in-network costs incurred after the deductible has been met. These plans offer a higher level of security for those who have chronic and costly conditions or a family history of expensive diseases like cancer or diabetes. A policy is considered high-deductible if the yearly deductible is more than $1,000, as opposed to $500 or less for low-deductible health plans.A study published in Health Affairs in March of 2019, however, suggests that high-deductible health plans may not be as great as they appear. In fact, they could be contributing to delayed diagnosis and treatment of breast cancer.The study examined one large national insurer’s claims data, specifically the data from 316,244 women whose employers switched from low- to high-deductible health insurance plans between 2004 and 2014. Compared to women on low-deductible health plans, those women who had low deductibles for at least a year prior to being switched to high-deductible plans waited longer on average to have diagnostic tests and treatments for breast cancer done.
Photo: Adobe Stock/smolaw11On average, low-income women with high deductibles waited 1.6 months longer than the low-deductible group for diagnostic breast imaging, 2.7 months for their first biopsy, 6.6 months for their first early-stage breast cancer diagnosis, and 8.7 months for chemotherapy treatment.The problem seems to lie in the fact that most people don’t keep enough money lying around to be able to pay their yearly deductibles. Take Susan, from Broomall, Pennsylvania, for example. She has a $6,000 deductible for herself and her child. When she found out she had a genetic variation which means there’s a 69 percent chance she’ll develop breast cancer at some point in her life, she chose to have increased surveillance to check for cancer, which would allow her to keep her breasts for now and continue breastfeeding her child. Now Susan must have a mammogram and an MRI every year, costing more than $3,000 together. Due to the high prices and the fact that she didn’t have that kind of liquid cash on hand, Susan got on a payment plan and chose to put off her 2018 screenings until she had finished paying her medical bills from 2017.However, even wealthy women don’t seem to be immune to the issue. Compared to affluent women with low deductibles, affluent women with high deductibles waited an average of 0.7 months longer for breast imaging, 1.9 months for their first biopsy, 5.4 months for their first early-stage breast cancer diagnosis, and 5.7 months for chemotherapy treatment.
Photo: Adobe Stock/romasetThe researchers say the same results hold true regardless not only of wealth but also of whether or not a woman lives in a metropolitan area and whether or not her neighborhood is mostly white or nonwhite. This evidence points even more strongly to the fact that it is the high-deductible health plans, rather than other factors, contributing to delayed diagnosis and treatment of breast cancer. However, some factors, such as the patient’s familiarity with their disease and their understanding of their insurance coverage and healthcare system, may play a role as well.“High-deductible plans are really the epitome of the access-to-care problem. People don’t have the liquid cash to meet their deductible, so you see delays in care or even avoiding treatment altogether,” says Dr. Veena Shankaran of the Hutchinson Cancer Research Center.For some women, waiting a little longer will not make a noticeable difference in the outcome. But for many, putting off a procedure that would diagnose or treat cancer or another serious health condition can have catastrophic consequences.
Photo: Adobe Stock/edwardoliveThis study is not the first of its kind to find that high-deductible health plans contribute to delayed diagnosis and treatment. Cardiovascular disease and diabetes are also on the list, so patients who are at risk of these diseases or who already have them may be prone to delaying treatment and therefore suffer from poorer health outcomes.“One thing that worries me,” says Dan Klein, president and chief executive officer of Patient Access Network Foundation, “is that Congress is very focused on lowering prescription drug prices. That’s a good goal, but it’s meaningless in an environment where patients still can’t access care or medications because of their deductibles.”According to the Kaiser Family Foundation, the number of people who have trouble meeting their deductibles has risen from 37 percent to 43 percent from 2015 to 2017. Share this article to draw more public attention to this under-represented issue!
Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...

ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ

Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

5-Year-Old Boy Surprised With Paycheck For Helping Electrical Company Fix His House

A young boy in England got quite the surprise when he was handed a check for a job well done! The boy’s mom, Laura-Nicole, shared...

SABCS 2021: New Research and Updates in Breast Cancer Treatment and Side Effects

The 2021 San Antonio Breast Cancer Symposium (SABCS) was held from December 7 to 10 in San Antonio, Texas, and online. In this podcast,...

Cancer Research UK publishes gender and ethnicity pay gap reports

As part of Cancer Research UK’s ongoing commitment to improving the diversity of the organisation, the charity has today published its gender pay gap...

Can mRNA Vaccines Help Treat Cancer?

January 20, 2022, by NCI Staff A technician working on mRNA vaccine production. Credit: Image used with permission from BioNTech The coronavirus pandemic has thrown a spotlight...

A Phase III Study of Spartalizumab in Combination with Dabrafenib and Trametinib Did Not Meet Primary Endpoint in BRAF V600–Mutated Metastatic Melanoma

COMBI-i did not show a statistically significant difference in investigator-assessed progression-free survival (PFS) in the broad population of patients with BRAF V600–mutated metastatic melanoma treated in...

Wawa Employee Saves Life Of Customer Who Stopped Breathing After A Seizure

When 19-year-old John Wallop arrived for his 16-hour shift behind the deli counter at Wawa in Millville, New Jersey, he thought it would just...